Shkrebneva I.I. - list of publications

LIPID-LOWERING THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE IN PRIMARY CARE PRACTICES: WHAT HAS CHANGED OVER 7 YEARS?

Article

Зырянов С.К., Фитилев С.Б., Возжаев А.В., Шкребнева И.И., Клюев Д.А., Степанян Л.Н., Данилова А.А., Цай А.Т., Ландышев Н.Н., Воронько Я.Г.

Cardiovascular Therapy and Prevention (Russian Federation). Vserossiiskoe Obshchestvo Kardiologov. Vol. 19. 2020. P. 78-86

RESULTS OF A PHASE I OPEN RANDOMIZED COMPARATIVE CROSSOVER CLINICAL TRIAL TO ASSESS THE SAFETY AND PHARMACOKINETICS OF GLURAZIM® (IMIGLUCERASE) IN COMPARISON WITH THE REFERENCE PRODUCT IN HEALTHY VOLUNTEERS

Article

Fitilev S.B., Vozzhaev A.V., Shkrebneva I.I., Kudlay D.A., Gapchenko E.V., Markova O.A., Borozinets A.Y., Kazarov A.A., Pantyushenko M.S.

Онкогематология. Общество с ограниченной ответственностью "Издательский дом "АБВ-пресс". Vol. 14. 2019. P. 73-83

MEDICATION ADHERENCE IN PATIENTS WITH CARDIOVASCULAR DISEASE: CURRENT VIEW OF THE PROBLEM

Article

Fitilev S.B., Vozzhaev A.V., Shkrebniova I.I., Kliuev D.A., Stepanyan L.N.

Качественная клиническая практика. Общество с ограниченной ответственностью Издательство ОКИ. 2019. P. 66-80

RESULTS OF A PHASE I OPEN RANDOMIZED COMPARATIVE CROSSOVER CLINICAL TRIAL TO ASSESS THE SAFETY AND PHARMACOKINETICS OF G LURAZYME® (IMIGLUCERASE) IN COMPARISON WITH THE REFERENCE PRODUCT IN HEALTHY VOLUNTEERS

Article

Fitilev S.B., Vozzhaev A.V., Shkrebneva I.I., Kudlay D.A., Gapchenko E.V., Markova O.A., Borozinets A.Y., Kazarov A.A., Pantyushenko M.S.

Онкогематология. Общество с ограниченной ответственностью "Издательский дом "АБВ-пресс". Vol. 14. 2019. P. 73-83

FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY)

Article

Fitilev S.B., Shkrebneva I.I., Vozzhaev A.V., Tsukanova K.O.

Rational Pharmacotherapy in Cardiology. Stolichnaya Izdatelskaya Kompaniya. Vol. 14. 2018. P. 244-251

ANALYSIS OF CHANGES IN PHARMACOTHERAPY OF STABLE ANGINA OVER THE FIVE-YEAR PERIOD AT SPECIALIZED OUT-PATIENT LEVEL OF MEDICAL CARE (PHARMACOEPIDEMIOLOGICAL STUDY)

Article

Tsukanova K.O., Fitilev S.B., Vozzhaev A.V., Shkrebneva I.I., Klyuev D.A.

Research Results in Pharmacology. Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет". Vol. 4. 2018. P. 47-58

СПЕЦИФИЧЕСКИЕ АСПЕКТЫ ПЕРВИЧНОЙ МЕДИЦИНСКОЙ ДОКУМЕНТАЦИИ В КЛИНИЧЕСКИХ ИССЛЕДОВАНИЯХ

Article

Возжаев А.В., Фитилев С.Б., Шкребнева И.И., Якушев В.А.

Организационные аспекты проведения клинических исследований. Группа Ремедиум. 2017. P. 87-90

SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES AMONG PATIENTS OF DIFFERENT AGE GROUPS WITH A HISTORY OF MYOCARDIAL INFARCTION BY THE EXAMPLE OF OUTPATIENT CARDIOLOGY INSTITUTION

Article

Fitilev S.B., Dimitrova D.A., Shkrebneva I.I., Vozzhaev A.V.

Rational Pharmacotherapy in Cardiology. Stolichnaya Izdatelskaya Kompaniya. Vol. 13. 2017. P. 317-322

NON-PHARMACOLOGICAL SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED AMBULATORY INSTITUTION

Article

Fitilev S.B., Shkrebneva I.I., Vozzhaev A.V., Tsukanova K.O., Dimitrova D.A.

Качественная клиническая практика. Общество с ограниченной ответственностью Издательство ОКИ. 2017. P. 25-28

DRUG INTERCHANGEABILITY: CLINICAL EFFICACY AND SAFETY

Article

Zyryanov S.K., Fitilev S.B., Shkrebneva I.I., Vozzhaev A.V.

Nevrologiya, Neiropsikhiatriya, Psikhosomatika. Ima-Press Publishing House. Vol. 9. 2017. P. 4-10

РОЛЬ ФАРМАЦЕВТИЧЕСКОГО ЗВЕНА В КЛИНИЧЕСКИХ ИССЛЕДОВАНИЯХ РАННИХ ФАЗ

Article

Возжаев А.В., Фитилев С.Б., Шкребнева И.И., Якушев В.А.

Организационные аспекты проведения клинических исследований. Группа Ремедиум. 2017. P. 20-22

SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)

Article

Fitilev S.B., Shkrebneva I.I., Vozzhaev A.V., Dimitrova D.A.

Rational Pharmacotherapy in Cardiology. Stolichnaya Izdatelskaya Kompaniya. Vol. 13. 2017. P. 171-177

FIRST CLINICAL STUDY OF RUSSIAN PEGINTERFERON ALFA-2B(ALGERON) IN HEALTHY VOLUNTEERS

Article

Fitilev S.B., Tukach A.I., Shkrebniova I.I., Ivanov R.A., Linkova Y.N., Chernovskaya T.V., Vozzhaev A.V., Yakushev V.A.

Клиническая фармакология и терапия. Общество с ограниченной ответственностью "Фармапресс". Vol. 23. 2014. P. 99-102

COMPARATIVE PHARMACOKINETIC STUDY OF BIOEQUIVALENCE OF METOPROLOL SUCCINATE PROLONGED DRUG FORMS

Article

Fitilev S.B., Yakushev V.A., Titarova Y.Y., Vozzhaev A.V., Shkrebniova I.I.

Клиническая фармакология и терапия. Общество с ограниченной ответственностью "Фармапресс". Vol. 21. 2012. P. 82-84

ASSESSING THE IMPLEMENTATION OF THE RECOMMENDATIONS ON SECONDARY CARDIOVASCULAR PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION (A PHARMACO-EPIDEMIOLOGIC STUDY)

Article

Oganov R.G., Lepakhin V.K., Fitilev S.B., Levin A.M., Shkrebneva I.I., Titarova Y.Y., Vozzhaev A.V.

Cardiovascular Therapy and Prevention (Russian Federation). Vserossiiskoe Obshchestvo Kardiologov. Vol. 8. 2009. P. 71-75

ОЦЕНКА ГИПОЛИПИДЕМИЧЕСКОЙ ТЕРАПИИ КАК КОМПОНЕНТА ВТОРИЧНОЙ ПРОФИЛАКТИКИ У ПАЦИЕНТОВ, ПЕРЕНЕСШИХ ИНФАРКТ МИОКАРДА (ФАРМАКОЭПИДЕМИОЛОГИЧЕСКОЕ ИССЛЕДОВАНИЕ)

Article

Фитилев С.Б., Возжаев А.В., Шкребнева И.И., Титарова Ю.Ю., Сычева Е.А., Журавлев Р.И.

Клиническая фармакология и терапия. Общество с ограниченной ответственностью "Фармапресс". Vol. 18. 2009. P. 95-96

QUALITY OF AMBULATORY PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE AND ITS COMPLICATIONS AMONG TYPE 2 DIABETES MELLITUS PATIENTS

Article

Oganov R.G., Lepakhin V.K., Fitilev S.B., Levin A.M., Shkrebneva I.I., Titarova Y.Y., Tsiruleva Y.Y.

Cardiovascular Therapy and Prevention (Russian Federation). Vserossiiskoe Obshchestvo Kardiologov. Vol. 7. 2008. P. 9-14

STABLE ANGINA PECTORIS: POPULATION TRENDS, DIAGNOSTICS, SECONDARY PREVENTION, AND ANTIANGINAL THERAPY

Article

Oganov R.G., Lepakhin V.K., Fitilev S.B., Levin A.M., Shkrebneva I.I., Titarova Yu.Yu., Doronkina M.K.

Cardiovascular Therapy and Prevention (Russian Federation). Vserossiiskoe Obshchestvo Kardiologov. Vol. 5. 2006. P. 49-54

SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MOSCOW POPULATION PATIENTS WITH MYOCARDIAL INFARCTION

Article

Oganov R.G., Lepakhin V.K., Fitilev S.B., Levin A.M., Shkrebneva I.I., Titarova Yu.Yu., Gromakovsaya S.V.

Cardiovascular Therapy and Prevention (Russian Federation). Vserossiiskoe Obshchestvo Kardiologov. Vol. 4. 2005. P. 53-60

Шкребнева И.И.

List of records

LIPID-LOWERING THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE IN PRIMARY CARE PRACTICES: WHAT HAS CHANGED OVER 7 YEARS?

RESULTS OF A PHASE I OPEN RANDOMIZED COMPARATIVE CROSSOVER CLINICAL TRIAL TO ASSESS THE SAFETY AND PHARMACOKINETICS OF GLURAZIM® (IMIGLUCERASE) IN COMPARISON WITH THE REFERENCE PRODUCT IN HEALTHY VOLUNTEERS

MEDICATION ADHERENCE IN PATIENTS WITH CARDIOVASCULAR DISEASE: CURRENT VIEW OF THE PROBLEM

RESULTS OF A PHASE I OPEN RANDOMIZED COMPARATIVE CROSSOVER CLINICAL TRIAL TO ASSESS THE SAFETY AND PHARMACOKINETICS OF G LURAZYME® (IMIGLUCERASE) IN COMPARISON WITH THE REFERENCE PRODUCT IN HEALTHY VOLUNTEERS

FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY)

ANALYSIS OF CHANGES IN PHARMACOTHERAPY OF STABLE ANGINA OVER THE FIVE-YEAR PERIOD AT SPECIALIZED OUT-PATIENT LEVEL OF MEDICAL CARE (PHARMACOEPIDEMIOLOGICAL STUDY)

СПЕЦИФИЧЕСКИЕ АСПЕКТЫ ПЕРВИЧНОЙ МЕДИЦИНСКОЙ ДОКУМЕНТАЦИИ В КЛИНИЧЕСКИХ ИССЛЕДОВАНИЯХ

SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES AMONG PATIENTS OF DIFFERENT AGE GROUPS WITH A HISTORY OF MYOCARDIAL INFARCTION BY THE EXAMPLE OF OUTPATIENT CARDIOLOGY INSTITUTION

NON-PHARMACOLOGICAL SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED AMBULATORY INSTITUTION

DRUG INTERCHANGEABILITY: CLINICAL EFFICACY AND SAFETY

РОЛЬ ФАРМАЦЕВТИЧЕСКОГО ЗВЕНА В КЛИНИЧЕСКИХ ИССЛЕДОВАНИЯХ РАННИХ ФАЗ

SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)

FIRST CLINICAL STUDY OF RUSSIAN PEGINTERFERON ALFA-2B(ALGERON) IN HEALTHY VOLUNTEERS

COMPARATIVE PHARMACOKINETIC STUDY OF BIOEQUIVALENCE OF METOPROLOL SUCCINATE PROLONGED DRUG FORMS

ASSESSING THE IMPLEMENTATION OF THE RECOMMENDATIONS ON SECONDARY CARDIOVASCULAR PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION (A PHARMACO-EPIDEMIOLOGIC STUDY)

ОЦЕНКА ГИПОЛИПИДЕМИЧЕСКОЙ ТЕРАПИИ КАК КОМПОНЕНТА ВТОРИЧНОЙ ПРОФИЛАКТИКИ У ПАЦИЕНТОВ, ПЕРЕНЕСШИХ ИНФАРКТ МИОКАРДА (ФАРМАКОЭПИДЕМИОЛОГИЧЕСКОЕ ИССЛЕДОВАНИЕ)

QUALITY OF AMBULATORY PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE AND ITS COMPLICATIONS AMONG TYPE 2 DIABETES MELLITUS PATIENTS

STABLE ANGINA PECTORIS: POPULATION TRENDS, DIAGNOSTICS, SECONDARY PREVENTION, AND ANTIANGINAL THERAPY

SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MOSCOW POPULATION PATIENTS WITH MYOCARDIAL INFARCTION

Other authors

Dimitrova D.A.

Vozzhaev A.V.